Last reviewed · How we verify
CLM2 topical gel — Competitive Intelligence Brief
phase 2
Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
CLM2 topical gel (CLM2 topical gel) — Glia, LLC. CLM2 topical gel is a treatment for pain relief by targeting the underlying cause of pain.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CLM2 topical gel TARGET | CLM2 topical gel | Glia, LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CLM2 topical gel CI watch — RSS
- CLM2 topical gel CI watch — Atom
- CLM2 topical gel CI watch — JSON
- CLM2 topical gel alone — RSS
Cite this brief
Drug Landscape (2026). CLM2 topical gel — Competitive Intelligence Brief. https://druglandscape.com/ci/clm2-topical-gel. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing